Wadchara Pumpradit

Learn More
OBJECTIVE To determine factors associated with baseline neurocognitive performance in HIV-infected participants enrolled in the Strategies for Management of Antiretroviral Therapy (SMART) neurology substudy. METHODS Participants from Australia, North America, Brazil, and Thailand were administered a 5-test neurocognitive battery. Z scores and the(More)
OBJECTIVES TMC125-C227, an exploratory phase II, randomized, controlled, open-label trial, compared the efficacy and safety of TMC125 (etravirine) with an investigator-selected protease inhibitor (PI) in nonnucleoside reverse transcriptase inhibitor (NNRTI)-resistant, protease inhibitor-naïve, HIV-1-infected patients. METHODS Patients were randomized to(More)
This research is a cross-sectional study to determine the frequency of neurocognitive impairment and psychiatric comorbidity among Thais maintained on highly active antiretroviral therapy (HAART) with undetectable plasma human immunodeficiency virus (HIV) RNA in the 2NN Cohort. Sixty-four subjects were evaluated with neurological examinations,(More)
Nineteen patients who completed a 27-month CD4-guided structured treatment interruption (STI) trial that showed similar efficacy in STI and continuous arms were asked to choose CD4-guided versus continuous HAART after the study ended. Six chose STI and 13 chose continuous HAART. Reasons for not choosing STIs were fear of developing HIV-related illnesses(More)
A 43-year-old female presented with severe sharp stabbing right-sided periorbital and retroorbital area headache, dull-aching unilateral jaw pain, eyelid swelling, ptosis, and tearing of the right eye but no rash. The pain episodes lasted five minutes to one hour and occurred 10-15 times per day with unremitting milder pain between the attacks. She later(More)
  • 1